Colorectal cancer (CRC) is a predominant life‐threatening cancer, with liver and peritoneal
metastases as the primary causes of death. Intestinal inflammation, a known CRC risk factor …

Systemic inflammation is a marker of poor prognosis preoperatively present in around 20%-
40% of colorectal cancer patients. The hallmarks of systemic inflammation include an …

Background & Aims Inflammatory bowel disease (IBD) is a chronic, relapsing inflammatory
disorder associated with an elevated risk of colorectal cancer (CRC). IBD-associated CRC …

PARP inhibitors drive increased DNA damage, particularly in tumors with existing defects in
DNA repair. This damage not only promotes immune priming through a range of molecular …

Immunotherapy strategies targeting immune checkpoints such as the CTLA4 and CD274
(programmed cell death 1 ligand 1, PD-L1)/PDCD1 (programmed cell death 1, PD-1) T-cell …

Colorectal cancer (CRC) is still considered as the third most frequent cancer in the world.
Microsatellite instability (MSI), inflammation, and microRNAs have been demonstrated as …

Colorectal cancer (CRC) is considered as the second most common cancer worldwide. For
the past few years, the role of immunotherapy has been extensively studied and it has been …

Background Although high T cell density is a strong favourable prognostic factor in
colorectal cancer, the significance of the spatial distribution of T cells is incompletely …

Background Inheritance patterns show familial clustering of gastrointestinal cancers, and
multiple germline conditions have now been identified that predispose to colorectal, gastric …

Simple Summary Mismatch-repair deficient (dMMR)/microsatellite instability high (MSI-H)
cancers encompass a subset of colorectal cancers (CRCs) sensitive to immune checkpoint …